IMA

ImageneBio Inc (IMA) 10Y Growth Potential Analysis (2026)

Invetso Score: 3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 3.2 (Weak)

No five-year revenue, EPS, or FCF CAGR is provided, limiting evidence of repeatable compounding versus peers with documented multi-year growth trajectories.

Negative TTM ROIC of -39.8% indicates current capital deployment is destroying value, which weakens reinvestment-led expansion relative to profitable peer growers.

Zero capex-to-revenue and zero R&D-to-revenue suggest limited disclosed reinvestment intensity, reducing visible capacity to fund scalable growth initiatives.

Extremely negative interest coverage of -614.2x implies earnings are insufficient to support growth investment, leaving the company behind peers with self-funding expansion.

Market Tailwinds

Score:

No segment, HHI, or largest-share data is provided, so there is no evidence of a differentiated demand tailwind versus peers.

The absence of disclosed growth metrics prevents confirmation that end-market expansion is translating into durable revenue acceleration.

Negative profitability and weak coverage ratios suggest the company is not currently converting market demand into scalable economic growth as effectively as peers.

Without filing-based evidence of expanding addressable demand, the long-term tailwind profile remains unproven relative to better-documented peer growth platforms.

Scalability Expansion

Score:

Negative ROIC and negative free-cash-flow yield indicate limited scalability today, because incremental growth is not yet producing attractive returns.

A cash conversion cycle of -485.2 days is unusual and may reflect working-capital distortion, but it does not by itself prove scalable compounding.

Net debt to EBITDA of 1.76x reduces flexibility for reinvestment, leaving less capacity to scale than peers with stronger balance sheets.

With no evidence of sustained revenue CAGR or margin expansion, the company’s long-term scaling profile remains materially below stronger compounders.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it signals that additional capital has not been translating into durable revenue or earnings growth.

Negative interest coverage materially limits financial optionality, making expansion more dependent on external funding than on internally generated cash flow.

Moderate leverage at 1.76x net debt to EBITDA constrains reinvestment capacity versus peers with cleaner balance sheets and stronger compounding ability.

The lack of disclosed multi-year growth history leaves execution durability unproven, which caps confidence in long-term scaling relative to peer benchmarks.

Overall Score

Score:

IMA shows weak 10-year growth potential because current capital deployment is unprofitable, leverage is meaningful, and there is no disclosed multi-year growth evidence to support compounding.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ImageneBio Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →